APO Research
Talk to an analyst

APO RESEARCH · REPORT

Febrile Neutropenia

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Febrile Neutropenia Market Analysis and Forecast 2026-2032

31 December 2025191 pages

Choose your research edition.

Industry ResearchFebrile Neutropenia Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Febrile Neutropenia Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Febrile Neutropenia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Febrile Neutropenia Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Febrile Neutropenia Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Febrile Neutropenia market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Febrile Neutropenia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Febrile Neutropenia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Febrile Neutropenia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Febrile Neutropenia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Febrile Neutropenia include BeyondSpring Inc., Eli Lilly and Company, Taiho Pharmaceutical Co., Ltd., Amgen Inc., Xenetic Biosciences, Inc. (XBIO), USV Private Limited, Richter Gedeon Nyrt., Hospira, Inc. and Aequus BioPharma, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Febrile Neutropenia, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Febrile Neutropenia, also provides the revenue of main regions and countries. Of the upcoming market potential for Febrile Neutropenia, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Febrile Neutropenia revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Febrile Neutropenia market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Febrile Neutropenia revenue, projected growth trends, production technology, application and end-user industry.

Febrile Neutropenia Segment by Company

BeyondSpring Inc.

Eli Lilly and Company

Taiho Pharmaceutical Co., Ltd.

Amgen Inc.

Xenetic Biosciences, Inc. (XBIO)

USV Private Limited

Richter Gedeon Nyrt.

Hospira, Inc.

Aequus BioPharma, Inc.

Febrile Neutropenia Segment by Type

Filgrastim Biosimilars

Pegfilgrastim

Pegfilgrastim Biosimilars

Vancomycin Hydrochloride

Others

Febrile Neutropenia Segment by Application

Hospitals

Clinics

Others

Febrile Neutropenia Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Febrile Neutropenia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Febrile Neutropenia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Febrile Neutropenia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Febrile Neutropenia in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Febrile Neutropenia company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Febrile Neutropenia revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Febrile Neutropenia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Filgrastim Biosimilars Major Player Table 3. Pegfilgrastim Major Player Table 4. Pegfilgrastim Biosimilars Major Player Table 5. Vancomycin Hydrochloride Major Player Table 6. Others Major Player Table 7. Global Febrile Neutropenia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Others Major Player Table 11. Febrile Neutropenia Industry Trends Table 12. Febrile Neutropenia Industry Drivers Table 13. Febrile Neutropenia Industry Opportunities and Challenges Table 14. Febrile Neutropenia Industry Restraints Table 15. Global Febrile Neutropenia Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Febrile Neutropenia Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Febrile Neutropenia Market Share by Region (2021-2026) Table 18. Global Febrile Neutropenia Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Febrile Neutropenia Market Share by Region (2027-2032) Table 20. Global Febrile Neutropenia Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Febrile Neutropenia Revenue Market Share by Players (2021-2026) Table 22. Global Febrile Neutropenia Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Febrile Neutropenia Key Players Headquarters & Area Served Table 24. Global Febrile Neutropenia Players, Product Type & Application Table 25. Global Febrile Neutropenia Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Febrile Neutropenia by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Febrile Neutropenia Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Febrile Neutropenia Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Febrile Neutropenia Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Febrile Neutropenia Revenue Market Share by Type (2021-2026) Table 32. Global Febrile Neutropenia Revenue Market Share by Type (2027-2032) Table 33. Global Febrile Neutropenia Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Febrile Neutropenia Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Febrile Neutropenia Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Febrile Neutropenia Revenue Market Share by Application (2021-2026) Table 37. Global Febrile Neutropenia Revenue Market Share by Application (2027-2032) Table 38. BeyondSpring Inc. Company Information Table 39. BeyondSpring Inc. Business Overview Table 40. BeyondSpring Inc. Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. BeyondSpring Inc. Febrile Neutropenia Product Portfolio Table 42. BeyondSpring Inc. Recent Development Table 43. Eli Lilly and Company Company Information Table 44. Eli Lilly and Company Business Overview Table 45. Eli Lilly and Company Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Eli Lilly and Company Febrile Neutropenia Product Portfolio Table 47. Eli Lilly and Company Recent Development Table 48. Taiho Pharmaceutical Co., Ltd. Company Information Table 49. Taiho Pharmaceutical Co., Ltd. Business Overview Table 50. Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Product Portfolio Table 52. Taiho Pharmaceutical Co., Ltd. Recent Development Table 53. Amgen Inc. Company Information Table 54. Amgen Inc. Business Overview Table 55. Amgen Inc. Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Amgen Inc. Febrile Neutropenia Product Portfolio Table 57. Amgen Inc. Recent Development Table 58. Xenetic Biosciences, Inc. (XBIO) Company Information Table 59. Xenetic Biosciences, Inc. (XBIO) Business Overview Table 60. Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Product Portfolio Table 62. Xenetic Biosciences, Inc. (XBIO) Recent Development Table 63. USV Private Limited Company Information Table 64. USV Private Limited Business Overview Table 65. USV Private Limited Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. USV Private Limited Febrile Neutropenia Product Portfolio Table 67. USV Private Limited Recent Development Table 68. Richter Gedeon Nyrt. Company Information Table 69. Richter Gedeon Nyrt. Business Overview Table 70. Richter Gedeon Nyrt. Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Richter Gedeon Nyrt. Febrile Neutropenia Product Portfolio Table 72. Richter Gedeon Nyrt. Recent Development Table 73. Hospira, Inc. Company Information Table 74. Hospira, Inc. Business Overview Table 75. Hospira, Inc. Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Hospira, Inc. Febrile Neutropenia Product Portfolio Table 77. Hospira, Inc. Recent Development Table 78. Aequus BioPharma, Inc. Company Information Table 79. Aequus BioPharma, Inc. Business Overview Table 80. Aequus BioPharma, Inc. Febrile Neutropenia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Aequus BioPharma, Inc. Febrile Neutropenia Product Portfolio Table 82. Aequus BioPharma, Inc. Recent Development Table 83. North America Febrile Neutropenia Revenue by Type (2021-2026) & (US$ Million) Table 84. North America Febrile Neutropenia Revenue by Type (2027-2032) & (US$ Million) Table 85. North America Febrile Neutropenia Revenue by Application (2021-2026) & (US$ Million) Table 86. North America Febrile Neutropenia Revenue by Application (2027-2032) & (US$ Million) Table 87. North America Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. North America Febrile Neutropenia Revenue by Country (2021-2026) & (US$ Million) Table 89. North America Febrile Neutropenia Revenue by Country (US$ Million) & (2027-2032) Table 90. Europe Febrile Neutropenia Revenue by Type (2021-2026) & (US$ Million) Table 91. Europe Febrile Neutropenia Revenue by Type (2027-2032) & (US$ Million) Table 92. Europe Febrile Neutropenia Revenue by Application (2021-2026) & (US$ Million) Table 93. Europe Febrile Neutropenia Revenue by Application (2027-2032) & (US$ Million) Table 94. Europe Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Europe Febrile Neutropenia Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Febrile Neutropenia Revenue by Country (US$ Million) & (2027-2032) Table 97. China Febrile Neutropenia Revenue by Type (2021-2026) & (US$ Million) Table 98. China Febrile Neutropenia Revenue by Type (2027-2032) & (US$ Million) Table 99. China Febrile Neutropenia Revenue by Application (2021-2026) & (US$ Million) Table 100. China Febrile Neutropenia Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Febrile Neutropenia Revenue by Type (2021-2026) & (US$ Million) Table 102. Asia Febrile Neutropenia Revenue by Type (2027-2032) & (US$ Million) Table 103. Asia Febrile Neutropenia Revenue by Application (2021-2026) & (US$ Million) Table 104. Asia Febrile Neutropenia Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Febrile Neutropenia Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Asia Febrile Neutropenia Revenue by Region (US$ Million) & (2021-2026) Table 107. Asia Febrile Neutropenia Revenue by Region (US$ Million) & (2027-2032) Table 108. SAMEA Febrile Neutropenia Revenue by Type (2021-2026) & (US$ Million) Table 109. SAMEA Febrile Neutropenia Revenue by Type (2027-2032) & (US$ Million) Table 110. SAMEA Febrile Neutropenia Revenue by Application (2021-2026) & (US$ Million) Table 111. SAMEA Febrile Neutropenia Revenue by Application (2027-2032) & (US$ Million) Table 112. SAMEA Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. SAMEA Febrile Neutropenia Revenue by Country (2021-2026) & (US$ Million) Table 114. SAMEA Febrile Neutropenia Revenue by Country (US$ Million) & (2027-2032) Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Febrile Neutropenia Image Figure 2. Global Febrile Neutropenia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Febrile Neutropenia Market Size Share 2021 VS 2025 VS 2032 Figure 4. Filgrastim Biosimilars Image Figure 5. Pegfilgrastim Image Figure 6. Pegfilgrastim Biosimilars Image Figure 7. Vancomycin Hydrochloride Image Figure 8. Others Image Figure 9. Global Febrile Neutropenia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Febrile Neutropenia Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Febrile Neutropenia Market Size (US$ Million) & (2021-2032) Figure 15. Global Febrile Neutropenia Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Febrile Neutropenia Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Febrile Neutropenia Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Febrile Neutropenia Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Febrile Neutropenia Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Febrile Neutropenia Revenue Market Share by Type (2021-2032) Figure 22. Global Febrile Neutropenia Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Febrile Neutropenia Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Febrile Neutropenia Revenue Market Share by Application (2021-2032) Figure 25. North America Febrile Neutropenia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Febrile Neutropenia Revenue Share by Type (2021-2032) Figure 27. North America Febrile Neutropenia Revenue Share by Application (2021-2032) Figure 28. North America Febrile Neutropenia Revenue Share by Country (2021-2032) Figure 29. United States Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Febrile Neutropenia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Febrile Neutropenia Revenue Share by Type (2021-2032) Figure 34. Europe Febrile Neutropenia Revenue Share by Application (2021-2032) Figure 35. Europe Febrile Neutropenia Revenue Share by Country (2021-2032) Figure 36. Germany Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Febrile Neutropenia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Febrile Neutropenia Revenue Share by Type (2021-2032) Figure 46. China Febrile Neutropenia Revenue Share by Application (2021-2032) Figure 47. Asia Febrile Neutropenia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Febrile Neutropenia Revenue Share by Type (2021-2032) Figure 49. Asia Febrile Neutropenia Revenue Share by Application (2021-2032) Figure 50. Asia Febrile Neutropenia Revenue Share by Region (2021-2032) Figure 51. Japan Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Febrile Neutropenia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Febrile Neutropenia Revenue Share by Type (2021-2032) Figure 59. SAMEA Febrile Neutropenia Revenue Share by Application (2021-2032) Figure 60. SAMEA Febrile Neutropenia Revenue Share by Country (2021-2032) Figure 61. Brazil Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Febrile Neutropenia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim Biosimilars
  • Pegfilgrastim
  • Pegfilgrastim Biosimilars
  • Vancomycin Hydrochloride
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • BeyondSpring Inc.
  • Eli Lilly and Company
  • Taiho Pharmaceutical Co., Ltd.
  • Amgen Inc.
  • Xenetic Biosciences, Inc. (XBIO)
  • USV Private Limited
  • Richter Gedeon Nyrt.
  • Hospira, Inc.
  • Aequus BioPharma, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Febrile Neutropenia Market by Type
  3. 1.2.1 Global Febrile Neutropenia Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Filgrastim Biosimilars
  5. 1.2.3 Pegfilgrastim
  6. 1.2.4 Pegfilgrastim Biosimilars
  7. 1.2.5 Vancomycin Hydrochloride
  8. 1.2.6 Others
  9. 1.3 Febrile Neutropenia Market by Application
  10. 1.3.1 Global Febrile Neutropenia Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Febrile Neutropenia Market Dynamics
  1. 2.1 Febrile Neutropenia Industry Trends
  2. 2.2 Febrile Neutropenia Industry Drivers
  3. 2.3 Febrile Neutropenia Industry Opportunities and Challenges
  4. 2.4 Febrile Neutropenia Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Febrile Neutropenia Market Perspective (2021-2032)
  2. 3.2 Global Febrile Neutropenia Growth Trends by Region
  3. 3.2.1 Global Febrile Neutropenia Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Febrile Neutropenia Market Size by Region (2021-2026)
  5. 3.2.3 Global Febrile Neutropenia Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Febrile Neutropenia Revenue by Players
  2. 4.1.1 Global Febrile Neutropenia Revenue by Players (2021-2026)
  3. 4.1.2 Global Febrile Neutropenia Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Febrile Neutropenia Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Febrile Neutropenia Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Febrile Neutropenia Key Players Headquarters & Area Served
  7. 4.4 Global Febrile Neutropenia Players, Product Type & Application
  8. 4.5 Global Febrile Neutropenia Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Febrile Neutropenia Market CR5 and HHI
  11. 4.6.3 2025 Febrile Neutropenia Tier 1, Tier 2, and Tier 3
5 Febrile Neutropenia Market Size by Type
  1. 5.1 Global Febrile Neutropenia Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Febrile Neutropenia Revenue by Type (2021-2032)
  3. 5.3 Global Febrile Neutropenia Revenue Market Share by Type (2021-2032)
6 Febrile Neutropenia Market Size by Application
  1. 6.1 Global Febrile Neutropenia Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Febrile Neutropenia Revenue by Application (2021-2032)
  3. 6.3 Global Febrile Neutropenia Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 BeyondSpring Inc.
  2. 7.1.1 BeyondSpring Inc. Company Information
  3. 7.1.2 BeyondSpring Inc. Business Overview
  4. 7.1.3 BeyondSpring Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  5. 7.1.4 BeyondSpring Inc. Febrile Neutropenia Product Portfolio
  6. 7.1.5 BeyondSpring Inc. Recent Developments
  7. 7.2 Eli Lilly and Company
  8. 7.2.1 Eli Lilly and Company Company Information
  9. 7.2.2 Eli Lilly and Company Business Overview
  10. 7.2.3 Eli Lilly and Company Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly and Company Febrile Neutropenia Product Portfolio
  12. 7.2.5 Eli Lilly and Company Recent Developments
  13. 7.3 Taiho Pharmaceutical Co., Ltd.
  14. 7.3.1 Taiho Pharmaceutical Co., Ltd. Company Information
  15. 7.3.2 Taiho Pharmaceutical Co., Ltd. Business Overview
  16. 7.3.3 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Product Portfolio
  18. 7.3.5 Taiho Pharmaceutical Co., Ltd. Recent Developments
  19. 7.4 Amgen Inc.
  20. 7.4.1 Amgen Inc. Company Information
  21. 7.4.2 Amgen Inc. Business Overview
  22. 7.4.3 Amgen Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Amgen Inc. Febrile Neutropenia Product Portfolio
  24. 7.4.5 Amgen Inc. Recent Developments
  25. 7.5 Xenetic Biosciences, Inc. (XBIO)
  26. 7.5.1 Xenetic Biosciences, Inc. (XBIO) Company Information
  27. 7.5.2 Xenetic Biosciences, Inc. (XBIO) Business Overview
  28. 7.5.3 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Product Portfolio
  30. 7.5.5 Xenetic Biosciences, Inc. (XBIO) Recent Developments
  31. 7.6 USV Private Limited
  32. 7.6.1 USV Private Limited Company Information
  33. 7.6.2 USV Private Limited Business Overview
  34. 7.6.3 USV Private Limited Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  35. 7.6.4 USV Private Limited Febrile Neutropenia Product Portfolio
  36. 7.6.5 USV Private Limited Recent Developments
  37. 7.7 Richter Gedeon Nyrt.
  38. 7.7.1 Richter Gedeon Nyrt. Company Information
  39. 7.7.2 Richter Gedeon Nyrt. Business Overview
  40. 7.7.3 Richter Gedeon Nyrt. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Richter Gedeon Nyrt. Febrile Neutropenia Product Portfolio
  42. 7.7.5 Richter Gedeon Nyrt. Recent Developments
  43. 7.8 Hospira, Inc.
  44. 7.8.1 Hospira, Inc. Company Information
  45. 7.8.2 Hospira, Inc. Business Overview
  46. 7.8.3 Hospira, Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Hospira, Inc. Febrile Neutropenia Product Portfolio
  48. 7.8.5 Hospira, Inc. Recent Developments
  49. 7.9 Aequus BioPharma, Inc.
  50. 7.9.1 Aequus BioPharma, Inc. Company Information
  51. 7.9.2 Aequus BioPharma, Inc. Business Overview
  52. 7.9.3 Aequus BioPharma, Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Aequus BioPharma, Inc. Febrile Neutropenia Product Portfolio
  54. 7.9.5 Aequus BioPharma, Inc. Recent Developments
8 North America
  1. 8.1 North America Febrile Neutropenia Revenue (2021-2032)
  2. 8.2 North America Febrile Neutropenia Revenue by Type (2021-2032)
  3. 8.2.1 North America Febrile Neutropenia Revenue by Type (2021-2026)
  4. 8.2.2 North America Febrile Neutropenia Revenue by Type (2027-2032)
  5. 8.3 North America Febrile Neutropenia Revenue Share by Type (2021-2032)
  6. 8.4 North America Febrile Neutropenia Revenue by Application (2021-2032)
  7. 8.4.1 North America Febrile Neutropenia Revenue by Application (2021-2026)
  8. 8.4.2 North America Febrile Neutropenia Revenue by Application (2027-2032)
  9. 8.5 North America Febrile Neutropenia Revenue Share by Application (2021-2032)
  10. 8.6 North America Febrile Neutropenia Revenue by Country
  11. 8.6.1 North America Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Febrile Neutropenia Revenue by Country (2021-2026)
  13. 8.6.3 North America Febrile Neutropenia Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Febrile Neutropenia Revenue (2021-2032)
  2. 9.2 Europe Febrile Neutropenia Revenue by Type (2021-2032)
  3. 9.2.1 Europe Febrile Neutropenia Revenue by Type (2021-2026)
  4. 9.2.2 Europe Febrile Neutropenia Revenue by Type (2027-2032)
  5. 9.3 Europe Febrile Neutropenia Revenue Share by Type (2021-2032)
  6. 9.4 Europe Febrile Neutropenia Revenue by Application (2021-2032)
  7. 9.4.1 Europe Febrile Neutropenia Revenue by Application (2021-2026)
  8. 9.4.2 Europe Febrile Neutropenia Revenue by Application (2027-2032)
  9. 9.5 Europe Febrile Neutropenia Revenue Share by Application (2021-2032)
  10. 9.6 Europe Febrile Neutropenia Revenue by Country
  11. 9.6.1 Europe Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Febrile Neutropenia Revenue by Country (2021-2026)
  13. 9.6.3 Europe Febrile Neutropenia Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Febrile Neutropenia Revenue (2021-2032)
  2. 10.2 China Febrile Neutropenia Revenue by Type (2021-2032)
  3. 10.2.1 China Febrile Neutropenia Revenue by Type (2021-2026)
  4. 10.2.2 China Febrile Neutropenia Revenue by Type (2027-2032)
  5. 10.3 China Febrile Neutropenia Revenue Share by Type (2021-2032)
  6. 10.4 China Febrile Neutropenia Revenue by Application (2021-2032)
  7. 10.4.1 China Febrile Neutropenia Revenue by Application (2021-2026)
  8. 10.4.2 China Febrile Neutropenia Revenue by Application (2027-2032)
  9. 10.5 China Febrile Neutropenia Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Febrile Neutropenia Revenue (2021-2032)
  2. 11.2 Asia Febrile Neutropenia Revenue by Type (2021-2032)
  3. 11.2.1 Asia Febrile Neutropenia Revenue by Type (2021-2026)
  4. 11.2.2 Asia Febrile Neutropenia Revenue by Type (2027-2032)
  5. 11.3 Asia Febrile Neutropenia Revenue Share by Type (2021-2032)
  6. 11.4 Asia Febrile Neutropenia Revenue by Application (2021-2032)
  7. 11.4.1 Asia Febrile Neutropenia Revenue by Application (2021-2026)
  8. 11.4.2 Asia Febrile Neutropenia Revenue by Application (2027-2032)
  9. 11.5 Asia Febrile Neutropenia Revenue Share by Application (2021-2032)
  10. 11.6 Asia Febrile Neutropenia Revenue by Country
  11. 11.6.1 Asia Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Febrile Neutropenia Revenue by Country (2021-2026)
  13. 11.6.3 Asia Febrile Neutropenia Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Febrile Neutropenia Revenue (2021-2032)
  2. 12.2 SAMEA Febrile Neutropenia Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Febrile Neutropenia Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Febrile Neutropenia Revenue by Type (2027-2032)
  5. 12.3 SAMEA Febrile Neutropenia Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Febrile Neutropenia Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Febrile Neutropenia Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Febrile Neutropenia Revenue by Application (2027-2032)
  9. 12.5 SAMEA Febrile Neutropenia Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Febrile Neutropenia Revenue by Country
  11. 12.6.1 SAMEA Febrile Neutropenia Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Febrile Neutropenia Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Febrile Neutropenia Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst